Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer.-Reference-Cited by-同舟云学术

Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:e15281-e15281
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Mohindra Nisha Anjali¹,Kircher Sheetal Mehta²,Nimeiri Halla Sayed²,Benson Al B.²,Rademaker Alfred³,Alonso Erin¹,Blatner Nicole²,Khazaie Khashayarsha⁴,Mulcahy Mary Frances⁵

Affiliation:

1. Northwestern Memorial Hospital, Chicago, IL

2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

3. Northwestern University, Feinberg School of Medicine, Chicago, IL

4. Mayo Clinic, Rochester, MN

5. Northwestern University, Chicago, IL

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.e15281

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity;2024-06-24

2. Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity;2024-06-24

3. Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity;2024-01-08

4. Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity;2023-10-18

5. The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities;The Journal of Pathology;2023-08